hTERT ICC Assay

INOVIQ has developed a proprietary immunocytochemistry (ICC) assay that detects hTERT, a component of telomerase, which is upregulated in most human epithelial cancers

Background

Telomerase is a well-recognised biomarker used by 85% of epithelial cancers to enable immortal cell replication. Translating telomerase into a biomarker of clinical activity is complex.

However, of the various telomerase components, INOVIQ has found assaying for hTERT is the most practical and efficient way of detecting the complex telomerase enzyme in a clinical setting.

hTERT contributes to cancer development and progression via multiple activities and high expression of hTERT is associated with TNM stage, lymphatic metastasis, and poor prognosis.

INOVIQ’s hTERT ICC Assay

INOVIQ’s proprietary hTERT test is an immunocytochemistry (ICC) assay that detects hTERT. Its first application is as an adjunct to urine cytology testing, the standard non-invasive test performed on urine samples being examined for the presence of cancerous cells (bladder cancer). Read more here.